Nocturne Acquisition Corporation - MBTCU STOCK NEWS

Nocturne Acquisition Corp. (NASDAQ:MBTCU) has postponed its Extraordinary General Meeting for the proposed business combination with Cognos Therapeutics, Inc. The meeting will now be held virtually on April 2, 2024. Shareholders can still vote on the proposals, with no changes made, and the record date remains December 29, 2023.

Nocturne Acquisition Corp. (NASDAQ:MBTCU) has postponed the Extraordinary General Meeting to vote on the business combination with Cognos Therapeutics, Inc. The meeting will now be held virtually on March 19, 2024, with no changes in the proposals. Shareholders can still vote even if they have sold their shares, and the deadline for redemption rights has been extended.

Nocturne Acquisition Corp. (NASDAQ:MBTCU) has announced a second postponement of the Extraordinary General Meeting for shareholders to vote on the proposed business combination with Cognos Therapeutics, Inc. The meeting, originally scheduled for January 30, 2024, has been rescheduled to February 27, 2024, and will be held virtually. Shareholders are encouraged to continue to solicit proxies, and the record date for the meeting remains December 29, 2023. The deadline for shareholders to exercise their redemption rights has been extended to two business days prior to the meeting.

Nocturne Acquisition Corp. (NASDAQ:MBTCU) has postponed the Extraordinary General Meeting for the proposed business combination with Cognos Therapeutics, Inc. to February 6, 2024. The meeting will be held virtually, and shareholders can continue to vote on the proposals. The record date for the meeting remains December 29, 2023, and shareholders who have already voted need not take any action. The deadline for redemption rights has been extended to two business days before the meeting.

Nocturne Acquisition Corporation (NASDAQ:MBTC) has submitted a registration statement to the SEC for a proposed business combination with Cognos Therapeutics, Inc. The combination aims to accelerate the research and advancement of Cognos' implantable drug delivery pump for the treatment of brain cancers and neurological diseases. The transaction is expected to close in Q4 2023 and the combined company will be renamed Cognos Therapeutics Holdings, Inc.

Nocturne Acquisition Corporation (NASDAQ: MBTC, MBTCU, MBTCR) announced a definitive business combination with Cognos Therapeutics, a company focused on innovative medical devices for neurological diseases. The transaction values Cognos at approximately $120 million and involves an all-stock deal where Cognos shareholders will receive Nocturne common stock valued at $10.30 each. The proposed combination, expected to close in the second or third quarter of 2023, aims to enhance Cognos' access to capital for advancing its SINNAIS™ Implantable Smart Pump, designed to improve drug delivery for brain cancer treatment.

Nocturne Acquisition Corp. (NASDAQ: MBTCU) announced a $1,150,000 deposit into its trust account, allowing an extension for its initial business combination period from July 5, 2022 to October 5, 2022. This payment translates to $0.10 per public share and aims to facilitate future acquisitions in disruptive technologies, particularly in the blockchain and artificial intelligence sectors. The Company focuses on targets with an equity value between $300 million and $1 billion.

Nocturne Acquisition Corp. (NASDAQ:MBTCU) has deposited $1,150,000 in its trust account, equating to $0.10 per public share. This extension allows the company to extend the deadline for its initial business combination by three months, from April 5, 2022 to July 5, 2022. The company aims to pursue acquisitions in sectors focusing on disruptive technologies in blockchain and artificial intelligence, targeting equity values between $300 million and $1 billion.